Stock data
Neumora Therapeutics, Inc. (NMRA)
Neumora Therapeutics, Inc. (NMRA) reported net income of -US$236.93M for fiscal 2025. The figures below come from the company's SEC filings.
Annual results
Data as of 2025-12-31
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | — | — | -US$241.16M | -US$236.93M | — |
| 2024 | — | — | -US$263.46M | -US$243.79M | — |
| 2023 | — | — | -US$252.10M | -US$235.93M | — |
| 2022 | — | — | -US$135.87M | -US$130.90M | — |
Quarterly results
Data as of 2026-06-30
| Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| 2026-06-30 | — | -US$43.08M | — |
| 2026-03-31 | — | -US$53.46M | — |
| 2025-12-31 | — | -US$59.45M | — |
| 2025-09-30 | — | -US$56.76M | — |
| 2025-06-30 | — | -US$52.73M | — |
| 2025-03-31 | — | -US$67.99M | — |
| 2024-12-31 | — | -US$58.82M | — |
| 2024-09-30 | — | -US$72.55M | — |
Sources
- Source: SEC EDGAR company facts
Charts, drawing tools, and the P/E calculator are in the app, free to use.